HEAD and neck Squamous cell Carcinoma Assessment with 68Ga trivehexiN PET/CT

Prospective study to evaluate the role of novel 68Ga Trivehexin PET/CT in assessing residual and recurrent head and neck squamous cell carcinoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/100165

Enrollment

Registered

2026-01-01

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx

Interventions

Intervention1: 68Ga Trivehexin PETCT: 68Ga Trivehexin PETCT is a type of novel PET scan, that will be performed on all eligible and consenting patients. The duration between 18F FDG PETCT and 68Ga Tri

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age, 18 years or above Patients with head and neck squamous cancer who has received definitive/curative intent treatment (Surgery or surgery + adjuvant CRT/RT or definitive CRT) Patients who have undergone a post treatment 18F-FDG PETCT scan during the follow up period Patients with post treatment 18F FDG PETCT scan showing NI-RADS score of 2 and above

Exclusion criteria

Exclusion criteria: Negative post treatment 18F-FDG PETCT scan (NI-RADS 1)

Design outcomes

Primary

Measure	Time frame
To find out the pattern of 68Ga Trivehexin PET/CT findings in patients of HNSCC, post definitive/curative treatment with an equivocal or positive 18F FDG PET/CT scan during the follow up period.Timepoint: 2 years from the date of last recruitment	—

Secondary

Measure	Time frame
1) To find out the diagnostic accuracy of 68Ga Trivehexin PET/CT in detecting residual/recurrent disease 2) To see if quantitative PET parameters (SUVmax, SUVmean, lesion to back ground ratio) and qualitative patterns of PET uptake in 68Ga Trivehexin PET scan can be used to differentiate post treatment inflammatory changes from viable residual/recurrent disease. 3) To compare the diagnostic accuracy of 68Ga Trivehexin PET/CT in detecting residual/recurrent disease 4) To assess the prognostic value of 68Ga Trivehexin scan in predicting progression free survivalTimepoint: 2 years from the date of last recruitment	—

Measure

Time frame

1) To find out the diagnostic accuracy of 68Ga Trivehexin PET/CT in detecting residual/recurrent disease 2) To see if quantitative PET parameters (SUVmax, SUVmean, lesion to back ground ratio) and qualitative patterns of PET uptake in 68Ga Trivehexin PET scan can be used to differentiate post treatment inflammatory changes from viable residual/recurrent disease. 3) To compare the diagnostic accuracy of 68Ga Trivehexin PET/CT in detecting residual/recurrent disease 4) To assess the prognostic value of 68Ga Trivehexin scan in predicting progression free survivalTimepoint: 2 years from the date of last recruitment

—

Countries

India

Contacts

Public ContactSayak Chodhury

Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)

choudhurysayak91@gmail.com7738714626

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026